Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 119-127

  Butler, Michelle M ^a   LaMarr, William A ^a,c   Foster, Kimberly A ^a,d   Barnes, Marjorie H ^a   Skow, Donna J ^a,e   Lyden, Patrick T ^a,f   Kustigian, Lauren M ^a   Zhi, Chengxin ^b   Brown, Neal C ^b   Wright, George E ^b   Bowlin, Terry L ^a  

^a MICROBIOTIX INC   (United States)

^b GLSYNTHESIS INC   (United States)

^c BioTrove Inc   (United States)

^d Biovest International   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Prime Performance Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 ETHYL 4 METHYLANILINO)URACIL; [1 CYCLOPROPYL 6,8 DIFLUORO 7 [1 (3 METHYL)PIPERAZINYL] 4 OXO 1,4 DIHYDROQUINOLINE] 3 CARBOXYLIC ACID; ANTIINFECTIVE AGENT; BACTERIAL DNA; COMPOUND 251D; DNA POLYMERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANILINE COMPOUNDS; ANTI-BACTERIAL AGENTS; BACILLUS; CELL LINE; CELL SURVIVAL; DNA GYRASE; DNA POLYMERASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 33845995869     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01311-05     Document Type: Article

References (44)

1. Aeschlimann, J. R., E. Hershberger, and M. J. Rybak. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918.
2. Barnes, M. H., and N. C. Brown. 1979. Antibodies to B. subtilis DNA polymerase III: use in purification and examination of homology among replication-specific DNA polymerases. Nucleic Acids Res. 6:1203-1219.
3. Barnes, M. H., R. A. Hammond, C. C. Kennedy, S. L. Mack, and N. C. Brown. 1992. Localization of the exonuclease and polymerase domains of Bacillus subtilis DNA polymerase III. Gene 111:43-49.
4. Barnes, M. H., W. A. LaMarr, and K. A. Foster. 2003. DNA gyrase and DNA topoisomerase of Bacillus subtilis: expression and characterization of recombinant enzymes encoded by the gyrA, gyrB and parC, parE genes. Protein Expr. Purif. 29:259-264.
5. Barnes, M. H., S. D. Miller, and N. C. Brown. 2002. DNA polymerases of low-GC gram-positive eubacteria: identification of the replication-specific enzyme encoded by dnaE. J. Bacteriol. 184:3834-3838.
6. Barnes, M. H., P. M. Tarantino, Jr., P. Spacciapoli, N. C. Brown, H. Yu, and K. Dybvig. 1994. DNA polymerase III of Mycoplasmapulmonis. isolation and characterization of the enzyme and its structural gene, polC. Mol. Microbiol. 13:843-854.
7. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1996. In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin. J. Antimicrob. Chemother. 38:324-327.
8. Blanche, F., B. Cameron, F. X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
9. Brown, N. C., L. W. Dudycz, and G. E. Wright. 1986. Rational design of substrate analogues targeted to selectively inhibit replication-specific DNA polymerases. Drugs Exp. Clin. Res. 12:555-564.
10. Brown, N. C., C. L. Weisseman III, and T. Matsushita. 1972. Inhibition of bacterial DNA replication by 6-p-hydroxyphenylazouracil. Nat. New Biol. 237:72-74.
11. Butler, M. M., L. W. Dudycz, N. N. Khan, G. E. Wright, and N. C. Brown. 1990. Development of novel inhibitor probes of DNA polymerase III based on dGTP analogs of the HPUra type: base, nucleoside and nucleotide derivatives of N2-(3,4-dichlorobenzyl)guanine. Nucleic Acids Res. 18:7381-7387.
12. Butler, M. M., D. J. Skew, R. O. Stephenson, P. T. Lyden, W. A. LaMarr, and K. A. Foster. 2002. Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3′-ethyl-4′-methylanilino) uracil. Antimicrob. Agents Chemother. 46:3770-3775.
13. Centers for Disease Control and Prevention. April 2006. Frequently asked questions about VISA/VRSA. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_FAQ.html.
14. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
15. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol Rev. 61:377-392.
16. Evans, M. E., and W. B. Titlow. 1998. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrob. Agents Chemother. 42:727.
17. Felmingham, D., R. R. Keinert, Y. Hirakata, and A. Rodloff. 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50(Suppl. S1):25-37.
18. Gordeev, M. F., C. Hackbarth, M. R. Barbachyn, L. S. Banitt, J. R. Gage, G. W. Luehr, M. Gomez, J. Trias, S. E. Morin, G. E. Zurenko, C. N. Parker, J. M. Evans, R. J. White, and D. V. Patel. 2003. Novel oxazolidinonequinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett. 13:4213-4216.
19. Hammond, R., M. H. Barnes, S. Mack, J. Mitchener, and N. C. Brown. 1991. Bacillus subtilis DNA polymerase III: complete sequence, overexpression and characterization of the polC gene. Gene 98:29-36.
20. Huang, Y.-P., and J. Ito. 1998. The hyperthermophilic bacterium Thermotoga maritima has two different classes of family C DNA polymerases: evolutionary implications. Nucleic Acids Res. 26:5300-5309.
21. Hubschwerlen, C., J. L. Specklin, D. K. Baeschlin, Y. Borer, S. Haefeli, C. Sigwalt, S. Schroeder, and H. H. Locher. 2003. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg. Med. Chem. Lett. 13:4229-4233.
22. Huycke, M. M., D. F. Sahm, and M. S. Gilmore. 1998. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg. Infect. Dis. 4:239-249.
23. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 45:2755-2764.
24. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350.
25. Kuhl, A., N. Svenstrup, C. Ladel, M. Otteneder, A. Binas, G. Schiffer, M. Brands, T. Lampe, K. Ziegelbauer, H. Rubsamen-Waigmann, D. Haebich, and K. Ehlert. 2005. Biological characterization of novel inhibitors of the gram-positive DNA polymerase IHC enzyme. Antimicrob. Agents Chemother. 49:987-995.
26. Longley, M. J., P. A. Ropp, S. E. Lim, and W. C. Copeland. 1998. Characterization of the native and recombinant catalytic subunit of human DNA polymerase γ. identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37:10529-10539.
27. Love, E., D. D'Ambrosio, and N. C. Brown. 1976. Mapping of the gene specifying DNA polymerase III of Bacillus subtilis. Mol. Gen. Genet. 144: 313-321.
28. Marshall, N. J., C. J. Goodwin, and S. J. Holt. 1995. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Growth Regul. 5:69-84.
29. Millichap, J., T. A. Ristow, G. A. Noskin, and L. R. Peterson. 1996. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn. Microbiol. Infect. Dis. 25:15-20.
30. Nagai, K., T. A. Davies, G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.
31. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA.
32. Ottiger, H. P., and U. Hübscher. 1984. Mammalian DNA polymerase alpha holoenzymes with possible functions at the leading and lagging strand of the replication fork. Proc. Natl. Acad. Sci. USA 81:3993-3997.
33. Pankey, G. A., and L. D. Sabath. 2004. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38:864-870.
34. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
35. Saiki, A. Y., L. L. Shen, C. M. Chen, J. Baranowski, and C. G. Lerner. 1999. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob. Agents Chemother. 43:1574-1577.
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
37. Stryer, L. 1981. Biochemistry, 2nd ed. W. H. Freeman and Co., New York, NY.
38. Tarantino, P. M., Jr., C. Zhi, J. J. Gambino, G. E. Wright, and N. C. Brown. 1999. 6-Anilinouracil-based inhibitors of Bacillus subtilis DNA polymerase III: antipolymerase and antimicrobial structure-activity relationships based on substitution at uracil N3. J. Med. Chem. 42:2035-2040.
39. Tarantino, P. M., Jr., C. Zhi, G. E. Wright, and N. C. Brown. 1999. Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. Antimicrob. Agents Chemother. 43:1982-1987.
40. Wright, G. E., and N. C. Brown. 1990. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol. Ther. 47:447-497.
41. Wright, G. E., and N. C. Brown. 1976. Inhibition of Bacillus subtilis DNA polymerase III by arylhydrazinopyrimidines. Novel properties of 2-thiouracil derivatives. Biochim. Biophys. Acta 432:37-48.
42. Zhi, C., Z. Y. Long, J. Gambino, W. C. Xu, N. C. Brown, M. Barnes, M. Butler, W. LaMarr, and G. E. Wright. 2003. Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase HIC and gram-positive bacterial growth. J. Med. Chem. 46:2731-2739.
43. Zhi, C., Z. Y. Long, A. Manikowski, N. C. Brown, P. M. Tarantino, Jr., K. Holm, E. J. Dix, G. E. Wright, K. A. Foster, M. M. Butler, W. A. LaMarr, D. J. Skow, I. Motorina, S. Lamothe, and R. Storer. 2005. Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils. J. Med. Chem. 48:7063-7074.
44. Zhi, C., Z. Y. Long, A. Manikowski, J. Comstock, W. C. Xu, N. C. Brown, P. M. Tarantino, Jr., K. A. Holm, E. J. Dix, G. E. Wright, M. H. Barnes, M. M. Butler, K. A. Foster, W. A. LaMarr, B. Bachand, R. Bethell, C. Cadilhac, S. Charron, S. Lamothe, I. Motorina, and R. Storer. 2006. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J. Med. Chem. 49:1455-1465.